BioNTech SE BNTX reported Q1 FY23 revenues of €1.28 billion, down from €6.37 billion a year ago, mainly due to lower commercial revenues from the supply and sales of the company's COVID-19 vaccines worldwide.
The company posted Q1 diluted EPS of €2.05, down from €14.24 a year ago.
The company says the COVID-19 vaccine franchise is focused on vaccine adaptation readiness ahead of the fall season and advancing next-generation vaccine candidates and combinations.
"In the first quarter of 2023, we expanded our toolkit of cutting-edge technologies to new modalities and added a novel immune checkpoint inhibitor candidate targeting CTLA-4 and two investigational antibody-drug conjugates to our arsenal against cancer," said Ugur Sahin said, CEO & Co-Founder.
"For the remainder of 2023, we are focused on advancing our disruptive platforms against solid tumors and accelerating clinical programs in infectious diseases of high global need," Sahin added.
Outlook: BioNTech reiterates FY23 COVID-19 vaccine revenue of approximately €5 billion compared to €17.1 billion in 2022.
Price Action: BNTX shares are up 3.57% at $112.30 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.